Over the last three decades, data from cancer studies have linked aberrant expression of GST isozymes with the development and expression of resistance to a variety of chemicals, including cancer drugs
Anecdotal reports from users have included: Commonly Reported: Injection site pain, redness, or swelling Mild dizziness Nausea Fatigue or drowsiness Less Commonly Reported: Anxiety or mood changes Heart palpitations Insomnia Loss of appetite Depression or anhedonia The FDA has noted that BPC-157 may pose an immunogenicity risk (triggering an immune response)
Kidney problems: Ongoing vomiting or diarrhea can lead to dehydration, which may strain your kidneys, leading to symptoms like swelling, fatigue, or reduced urination
These conditions can significantly impact disease progression and prognosis during the treatment of T2DM and obesity
Long-term safety, heart-and-blood-vessel outcomes, rare events, and what happens after stopping are still unknown - these are the questions Phase 3 is built to answer
Lisdexamfetamine is a Schedule II controlled substance with potential for abuse and dependence